# OnCo record nct07252739 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07252739/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07252739", "NCT07252739" ;
  schema:name "KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)"@en ;
  schema:alternateName "KEYMAKER-U01"@en ;
  schema:description "A phase 2 trial of Calderasib, Pembrolizumab, Cetuximab and Sacituzumab tirumotecan in advanced solid tumours, run by Merck Sharp & Dohme LLC, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07252739/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07252739> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2025-12-19" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/calderasib/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/sacituzumab-tirumotecan/> ;
  onco:companies <https://onco.cc/companies/merck/> .